Working together to exploit a rich seam of novel epigenetic targets for cancer


Session type:

Chas Bountra1
1University of Oxford, Oxford, UK


During my presentation, I will discuss:

  • How we are pooling the expertise and infrastructure of several big pharmas, withdisease and clinical expertise, and patients resources in academia, to accelerate novel target identification.
  • Novel epigenetic targets which are worth further exploration.
  • How these efforts are facilitating science and proprietary programmes, including the creation of new biotechs.
  • Our plans to establish a nationwide, human disease platform for novel epigenetic target prioritisation.